Sale!

KCNQ3 Gene Seizures Benign Neonatal Type 2 Genetic Test

Name: KCNQ3 Gene Seizures Benign Neonatal Type 2 Genetic Test
SKU: TEST-1971
Price: 4400 AED
Availability: InStock

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The KCNQ3 Gene Seizures Benign Neonatal Type 2 Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the KCNQ3 gene, which are associated with Benign Neonatal Seizures Type 2 (BNST2). This condition is characterized by the onset of seizures within the first days or weeks of life, which usually resolve spontaneously within the first year. Although the seizures are generally not harmful to the infant’s long-term development, early and accurate diagnosis is crucial for appropriate management and to alleviate parental concerns.

The test involves analyzing the patient’s DNA to detect any genetic alterations in the KCNQ3 gene, which plays a critical role in the proper functioning of nerve cells in the brain. Mutations in this gene can disrupt the normal flow of potassium ions in neurons, leading to the development of seizures.

Priced at 4400 AED, the test is conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities and high standards of accuracy and reliability. This test is particularly valuable for families with a history of BNST2, as it can provide essential information for early intervention strategies and help in understanding the genetic predisposition to the condition within the family.

Description

KCNQ3 Gene Seizures benign neonatal type 2 Genetic Test

Components: KCNQ3 Gene Seizures benign neonatal type 2 Genetic Test

Price: 4400.0 AED

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Method: NGS Technology

Test type: Neurological Disorders

Doctor: Neurologist

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for KCNQ3 Gene Seizures, benign neonatal, type 2 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with KCNQ3 Gene Seizures, benign neonatal, type 2.

Test Details: The KCNQ3 gene is responsible for encoding a potassium channel that helps regulate the electrical activity in neurons. Mutations in this gene can lead to a condition called benign neonatal seizures, type 2. Benign neonatal seizures, type 2, is a rare genetic disorder characterized by seizures that typically start within the first few days of life and resolve by three to four months of age. These seizures are generally not associated with any underlying brain abnormalities and have a good prognosis, as they tend to resolve without any long-term neurological deficits.

NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that allows for the simultaneous analysis of multiple genes or even the entire exome (all the coding regions of genes) in a single test. It is a powerful tool for identifying genetic mutations associated with various diseases, including KCNQ3 gene mutations related to benign neonatal seizures, type 2. NGS genetic testing involves obtaining a DNA sample, typically through a blood or saliva sample, and analyzing it using specialized laboratory techniques. The DNA is sequenced, and the resulting data is analyzed to identify any genetic variations or mutations in the KCNQ3 gene or other relevant genes.

By performing NGS genetic testing, healthcare providers can confirm a diagnosis of benign neonatal seizures, type 2 by identifying specific mutations in the KCNQ3 gene. This information can be valuable for providing appropriate medical management, genetic counseling, and family planning guidance. It is important to note that genetic testing should be ordered and interpreted by healthcare professionals with expertise in genetics, such as geneticists or genetic counselors, to ensure accurate and appropriate interpretation of the results.

Test Name	KCNQ3 Gene Seizures benign neonatal type 2 Genetic Test
Components
Price	4400.0 AED
Sample Condition	Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery	3 to 4 Weeks
Method	NGS Technology
Test type	Neurological Disorders
Doctor	Neurologist
Test Department:	Genetics
Pre Test Information	Clinical History of Patient who is going for KCNQ3 Gene Seizures, benign neonatal, type 2 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with KCNQ3 Gene Seizures, benign neonatal, type 2
Test Details	The KCNQ3 gene is responsible for encoding a potassium channel that helps regulate the electrical activity in neurons. Mutations in this gene can lead to a condition called benign neonatal seizures, type 2. Benign neonatal seizures, type 2, is a rare genetic disorder characterized by seizures that typically start within the first few days of life and resolve by three to four months of age. These seizures are generally not associated with any underlying brain abnormalities and have a good prognosis, as they tend to resolve without any long-term neurological deficits. NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that allows for the simultaneous analysis of multiple genes or even the entire exome (all the coding regions of genes) in a single test. It is a powerful tool for identifying genetic mutations associated with various diseases, including KCNQ3 gene mutations related to benign neonatal seizures, type 2. NGS genetic testing involves obtaining a DNA sample, typically through a blood or saliva sample, and analyzing it using specialized laboratory techniques. The DNA is sequenced, and the resulting data is analyzed to identify any genetic variations or mutations in the KCNQ3 gene or other relevant genes. By performing NGS genetic testing, healthcare providers can confirm a diagnosis of benign neonatal seizures, type 2 by identifying specific mutations in the KCNQ3 gene. This information can be valuable for providing appropriate medical management, genetic counseling, and family planning guidance. It is important to note that genetic testing should be ordered and interpreted by healthcare professionals with expertise in genetics, such as geneticists or genetic counselors, to ensure accurate and appropriate interpretation of the results.